Glaucoma is a progressive optic neuropathy characterized by a specific pattern of optic nerve head and visual field damage. Because of the absence of noticeable symptoms, glaucoma often leads to substantial visual loss before diagnosis. Until now, glaucoma remains incurable although its progression can be retarded by lowering the IOP by anti-glaucoma drugs. Neuroprotection has been proposed to facilitate in delaying the disease progression, but has not yet been successfully developed as an alternative treatment option. Because of the issues regarding drug resistance and patient compliance, novel agents with more potent and long-lasting actions are required. Baicalein (5,6,7-trihydroxyflavone) has a broad spectrum of bioactivity and has been shown that baicalein can be used in the treatment of neuropathies and cognitive impairment.